Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGNFree Report) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Price Performance

Shares of NASDAQ:EVGN opened at $0.64 on Wednesday. The firm has a market capitalization of $26.34 million, a PE ratio of -1.39 and a beta of 1.40. The business has a 50 day simple moving average of $0.69 and a two-hundred day simple moving average of $0.77. Evogene has a 1 year low of $0.45 and a 1 year high of $1.44.

Evogene (NASDAQ:EVGNGet Free Report) last announced its quarterly earnings results on Thursday, May 23rd. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $4.19 million during the quarter. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%.

Hedge Funds Weigh In On Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets raised its holdings in Evogene Ltd. (NASDAQ:EVGNFree Report) by 30.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

(Get Free Report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

See Also

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.